Your selection

Innovation / 24.05.2024
Eckert & Ziegler receives “Best Managed Companies Award”

Eckert & Ziegler SE (ISIN DE0005659700) was honored with the “Best Managed Companies Award” at an award ceremony in Frankfurt am Main on May 23, 2024. With this award, Deloitte Private, UBS, Frankfurter Allgemeine Zeitung and the Federation of German Industries (Bundesverband der Deutschen Industrie e.V.) recognize outstandingly managed medium-sized companies.

Following a multi-level application process, the participating companies were assessed for their excellence in the following core areas: strategy, productivity and innovation, culture and commitment as well as finance and governance. High performance in all four areas is a prerequisite for the award. The award winners were then selected by a jury consisting of renowned representatives from business, science and the media.

“We are delighted to receive the Best Managed Companies award and consider this to be confirmation of our long-term corporate strategy. The award is also an acknowledgement of our employees, who contribute significantly to the success of our company every day with great dedication,” says Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE. “This is a fantastic team achievement, which we are very excited about.”

“Eckert & Ziegler is an outstanding example of a Best Managed Company that impresses with its powerful mix of vision, productivity, innovative spirit and strong, value-oriented leadership. In addition, the company has the remarkable ability to harmonize attractive work and economic growth. It is an example of how companies can make a big difference in their region,” emphasizes Dr. Christine Wolter, Partner and Lead of Deloitte Private.

About Eckert & Ziegler
Eckert & Ziegler SE with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

About Best Managed Companies Program
The Best Managed Companies Program is a competition and seal of quality for successful medium-sized companies. It was launched by Deloitte in Canada in the 1990s and has since been successfully introduced in more than 45 countries. Companies with an annual turnover of at least 150 million € and headquarters in Germany can apply. In addition, the companies must be medium-sized or family-owned and show successful economic development in recent years.

Press Release:
Eckert & Ziegler receives “Best Managed Companies Award”

Source: Eckert & Ziegler Eckert & Ziegler Strahlen- und Medizintechnik AG

Overview News

News Buch Berlin

OMEICOS Completes Enrollment of PMD-OPTION Study in Primary Mitochondrial Disease

Interim data confirms OMT-28's strong safety profile in PMD patients, top-line data expected mid-2025

more ...

A new culprit in Huntington’s disease

Researchers in Berlin and Düsseldorf have implicated a new gene in the progression of Huntington’s disease in a brain organoid model. The gene may contribute to brain abnormalities much earlier than p...

more ...

Eckert & Ziegler opens new facilities for radiopharmaceutical plant engineering in Dresden

In the presence of the Saxon State Ministers Martin Dulig and Thomas Schmidt as well as the Mayor of Dresden Dirk Hilbert, the medical technology company Eckert & Ziegler today inaugurated its new 1,7...

more ...

Events Buch Berlin

30.09.2024, 10:00
„Schnell dabei“ – Karrierebus am 30. September auf dem Pankower Anger

Interessierte haben die Möglichkeit, sich über die Tätigkeit als Erzieher:innen in Jugendfreizeiteinrichtungen oder in der Sachbearbeitung der Kitagutscheinstelle des Jugendamtes zu informieren und gl...

more ...

08.10.2024, 09:00
GMP Biotech Summer School

Good Manufacturing Practice (GMP) Basic Course Biotechnology (English) & ATMPs

more ...

08.10.2024, 16:00
Die CRISPR/Cas-Methode: Chancen und Risiken für die Medizin

VORLESUNGSREIHE „NEUE WEGE IN DER BIOMEDIZIN“ für Lehrkräfte, Schüler:innen und Interessierte

more ...

This website is supported by: